News and Announcements
Proteomics International Expands Diagnostics Portfolio to Endometriosis
- Published August 24, 2016 10:56AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th August 2016, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is applying its disruptive proteomics technology platform to new areas of significant unmet medical need.
- PILL is investigating protein ‘fingerprints’ that can diagnose endometriosis from a simple blood test.
- Endometriosis affects one in ten women in their reproductive years and costs Australia $7.7 billion annually.
- The research employs PILL’s proven Promarker platform, which has already been used to develop a predictive test for diabetic kidney disease, and could deliver results within 12 months.
Perth company PILL is investigating proteins in the blood that are associated with endometriosis, paving the way for the development of a quick and easy diagnostic test for the painful condition.
Endometriosis occurs when the tissues that line the uterus spread and surround other organs. The condition affects one in ten women in their reproductive years (15-49) and costs $12,000 per year for every person diagnosed – both incidence and health burden are comparable with diabetes.
To view the full announcement, please click on the button below.